Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies

Wasim S. El Nekidy, Mooza Al Ali, Emna Abidi, Islam M. Ghazi, Nizar Attallah, Rania El Lababidi, Fadi Hijazi, Jihad MallatClinical 2023 · DOI

Abstract

The used doses of C/T in this study were higher than those approved by the U.S. FDA, while clinical success is uncertain. Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration.
BibTeX
@inproceedings{nekidy2023clinical,
  author = {Wasim S. El Nekidy and Mooza Al Ali and Emna Abidi and Islam M. Ghazi and Nizar Attallah and Rania El Lababidi and Fadi Hijazi and Jihad Mallat},
  title = {{Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies}},
  booktitle = {Clinical},
  year = {2023},
  doi = {10.5414/cn111166},
}

Loading related content...

Figure